在CAR工程淋巴原体中准BCL11B驱动着长期抗白血病活性的NK类细胞的发展
Franziska Baatz1, Arnab Ghosh2, Jessica Herbst1
1Department of Pediatric Hematology, Department of Oncology and Blood Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Molecular therapy : the journal of the American Society of Gene Therapy
|February 16, 2025
概括
在淋巴细胞原始体中准BCL11B可增强CAR工程细胞疗法. Bcl11b淘汰赛促进了抗原独立的抗白血病反应,改善了CARiK细胞对白血病的疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 基因编辑 基因编辑
- 癌症治疗 癌症治疗
背景情况:
- 化学抗原受体 (CAR) 疗法在白血病治疗方面表现有前途.
- 通过CAR诱导的B细胞CLL/淋巴瘤11B (BCL11B) 的抑制对于CAR诱导的杀手细胞 (CARiK) 的发展至关重要.
- BCL11B是一个关键的转录因子,调节淋巴细胞分化.
研究的目的:
- 研究CRISPR-Cas9介导的Bcl11b淘汰在调节CARiK细胞发育和抗白血病活性中的作用.
- 评估单独或与CAR表达相结合的Bcl11b淘汰对淋巴细胞原始体的独特影响.
- 探索Bcl11b向增强CAR工程淋巴原生细胞治疗的潜力.
主要方法:
- 在人类和小鼠早期淋巴细胞原始体中,CRISPR-Cas9基因编辑以淘汰Bcl11b.
- 通过CAR工程的淋巴细胞前代细胞的生成.
- 编辑后代的采养转移到造血干细胞接受者中.
- 在体内对抗白血病免疫反应和细胞活性的评估.
主要成果:
- 在早期的淋巴原始体中,Bcl11b淘汰明显调节了CARiK细胞的发育.
- 经过Bcl11b编辑的祖先在移植后表现出与天生的类似,抗原独立的抗白血病免疫反应.
- 淋巴细胞原始体具有Bcl11b淘汰和CAR表达,在体内表现出长时间的抗白血病活性.
- 综合编辑策略增强了整体抗白血病功能.
结论:
- 向BCL11B是一种可行的策略,可以增强CAR工程淋巴细胞原生细胞的抗白血病功能.
- Bcl11b绝杀可以赋予抗原独立的抗白血病活性,补充CAR介导的抗原特异性反应.
- 这些发现为开发改善的基于CAR的白血病免疫疗法提供了基础.
相关概念视频
01:23Cells of the Adaptive Immune Response
895
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
895
01:24B Cell Activation and Differentiation
1.5K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.5K